Lite Strategy LITS
NASDAQ LITS
$0.99 +0.05 (+4.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Other Accumulated Expenses (2011 - 2026)

Lite Strategy (LITS) posted quarterly Other Accumulated Expenses of $64000.0 for Q1 2026, down 14.67% year-over-year from $75000.0 in Q1 2025, and little changed quarter-over-quarter from $64000.0 in Q4 2025.

Lite Strategy (LITS) Other Accumulated Expenses (2011 - 2026) Analysis & Trends

Lite Strategy's Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $64000.0 for Q1 2026.

  • In Q1 2026, Other Accumulated Expenses fell 14.67% year-over-year to $64000.0; the TTM figure through Mar 2026 stood at $64000.0 (down 14.67% YoY), while the FY2025 annual figure was $27000.0, down 20.59% from the prior year.
  • Other Accumulated Expenses for Q1 2026 stood at $64000.0, roughly flat from $64000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $186000.0 in Q2 2023, with the low at $27000.0 in Q2 2025.
  • The 5-year median for Other Accumulated Expenses is $64000.0 (2025), against an average of $87307.7.
  • The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses surged 141.67% in 2022, then slumped 81.72% in 2024.
  • Lite Strategy's Other Accumulated Expenses stood at $174000.0 in 2022, then fell by 4.6% to $166000.0 in 2023, then slumped by 65.06% to $58000.0 in 2024, then increased by 10.34% to $64000.0 in 2025, then changed by 0.0% to $64000.0 in 2026.
  • Business Quant data shows LITS's Other Accumulated Expenses at $64000.0 in Q1 2026, $64000.0 in Q4 2025, and $30000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Lite Strategy 35.71 Mn 28.17 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 64,000.00
Dec 31, 2025 64,000.00
Sep 30, 2025 30,000.00
Jun 30, 2025 27,000.00
Mar 31, 2025 75,000.00
Dec 31, 2024 58,000.00
Sep 30, 2024 55,000.00
Jun 30, 2024 34,000.00
Mar 31, 2024 94,000.00
Dec 31, 2023 166,000.00
Sep 30, 2023 108,000.00
Jun 30, 2023 186,000.00
Jun 30, 2022 174,000.00
Jun 30, 2021 72,000.00
Jun 30, 2020 111,000.00
Jun 30, 2018 203,000.00
Jun 30, 2017 138,000.00
Jun 30, 2016 60,000.00
Jun 30, 2015 79,000.00
Jun 30, 2014 107,000.00